Skip to main content
S&P 5007,585.73-0.45%DOW52,093.11-0.63%NASDAQ25,981.57-0.78%BTC$75,900.00-1.51%ETH$2,404.54-3.20%GOLD$4,387.30+1.26%OIL$103.71-2.00%
Smart Investors Daily
AS

NASDAQ · ASND

Ascendis Pharma A/S

Healthcare · Biotechnology

$239.77

Down-$25.15 (-9.49%)

Updated Sep 16, 2026, 8:36 AM

SID Score

6.2/10

Composite research score

Smart Money

58/100

Neutral

Market cap
14.33B
P/E ratio
-53.27
Dividend yield
0.00%
52-week range
$203.80 – $282.15
Volume
2.96M
Avg. volume
711.81K

Price performance

ASND price history

1M range · 20 trading sessions · Daily adjusted prices

ASND closed at $239.77 after 20 trading sessions, down 3.65% for the selected period.

Last close
$239.77
Period change
-3.65%
Period low
$239.77
Period high
$271.12
Daily close
View OHLC price history
ASND OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 15, 2026$257.17$257.53$228.56$239.772.96M
Sep 14, 2026$265.00$265.50$260.00$264.92417.85K
Sep 11, 2026$263.34$266.34$259.48$263.515443.61K
Sep 10, 2026$260.00$262.17$258.01$261.23505.04K
Sep 9, 2026$270.89$272.3703$260.75$260.81497.43K
Sep 8, 2026$263.41$272.4665$262.32$270.09653.37K
Sep 4, 2026$267.96$271.14$265.22$270.56723.52K
Sep 3, 2026$266.94$272.44$265.80$271.121.02M
Sep 2, 2026$261.39$268.71$257.52$267.31418.3K
Sep 1, 2026$261.65$266.6301$256.275$260.25610.6K
Aug 31, 2026$247.65$268.98$247.65$263.041.03M
Aug 28, 2026$248.11$250.23$246.30$247.91314.79K
Aug 27, 2026$249.73$250.69$248.41$249.36189.54K
Aug 26, 2026$252.84$252.84$249.16$250.25237.43K
Aug 25, 2026$253.01$256.60$251.325$252.99333.52K
Aug 24, 2026$256.35$256.35$247.0276$251.95329.92K
Aug 21, 2026$253.62$257.885$252.87$253.29363.77K
Aug 20, 2026$256.65$260.98$253.21$254.81533.64K
Aug 19, 2026$255.00$261.61$251.11$259.62541.22K
Aug 18, 2026$246.47$253.55$245.68$248.85452.63K

Latest ASND news

The latest Smart Investors Daily articles mentioning ASND.

Stock researchCompany · Overview

ASND research

Overview

Company profile and research snapshot.

Company profile

Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$246.67
Implied upside
—
Analysts
—
ASND recent ratings
DateFirmRatingTarget
Sep 15, 2026Raymond JamesOutperform—
Sep 2, 2026OppenheimerOutperform—
Sep 1, 2026WedbushOutperform—
Sep 1, 2026Morgan StanleyOverweight—
Aug 31, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 10, 2026

Ascendis Pharma Says Growth Drug Shows Benefits in Infants

Ascendis Pharma A/S (NASDAQ:ASND) on Wednesday announced Week 52 data from the open-label sentinel cohort of its reACHin trial. The data showed that once-weekly TransCon CNP (navepegritide) provided stabilization or improvement in foramen magnum stenosis alongside linear growth benefits in infants with achondroplasia aged 0 to under 2 years. Read Also: Biomarin, Ascendis Reach Mutually Beneficial Agreement Ending Global Patent Disputes Growth And Cranio-Cervical Health Treatment with TransCon CN

Yahoo · Sep 9, 2026

First Infant Data from Ascendis Trial of Once-Weekly TransCon CNP (Navepegritide) Presented at ESPE 2026

– Achondroplasia Foramen Magnum Score was stable or improved between baseline and Week 52 with TransCon CNP treatment – Treatment with TransCon CNP increased linear growth in the sentinel cohort, with an improvement in ACH-specific supine length Z-score of +0.42 from baseline through Week 52 – Treatment with TransCon CNP was generally well tolerated, with no reports of injection site reactions over the 52-week treatment period COPENHAGEN, Denmark, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Ascendis Phar

Benzinga · Sep 9, 2026

Ascendis Announces Week 52 Data From Open-Label Sentinel Cohort Portion Of reACHin Trial Showing Treatment With Once-Weekly TransCon CNP Provided Stabilization Or Improvement In Foramen Magnum Stenosis And Linear Growth Benefits In Infants With Achondroplasia

– Achondroplasia Foramen Magnum Score was stable or improved between baseline and Week 52 with TransCon CNP treatment – Treatment with TransCon CNP increased linear growth in the sentinel cohort, with an improvement in

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By